JPWO2008012949A1 - ジ(ピリミジンヌクレオシド5’−)ポリホスフェートの製造法 - Google Patents
ジ(ピリミジンヌクレオシド5’−)ポリホスフェートの製造法 Download PDFInfo
- Publication number
- JPWO2008012949A1 JPWO2008012949A1 JP2008526680A JP2008526680A JPWO2008012949A1 JP WO2008012949 A1 JPWO2008012949 A1 JP WO2008012949A1 JP 2008526680 A JP2008526680 A JP 2008526680A JP 2008526680 A JP2008526680 A JP 2008526680A JP WO2008012949 A1 JPWO2008012949 A1 JP WO2008012949A1
- Authority
- JP
- Japan
- Prior art keywords
- uridine
- pyrimidine nucleoside
- triphosphate
- pyrimidine
- polyphosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002718 pyrimidine nucleoside Substances 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 35
- 229920000388 Polyphosphate Polymers 0.000 title claims abstract description 27
- 239000001205 polyphosphate Substances 0.000 title claims abstract description 27
- 235000011176 polyphosphates Nutrition 0.000 title claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 239000001226 triphosphate Substances 0.000 claims abstract description 25
- 229910052751 metal Inorganic materials 0.000 claims abstract description 23
- 239000002184 metal Substances 0.000 claims abstract description 23
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000011178 triphosphate Nutrition 0.000 claims abstract description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 10
- 239000011777 magnesium Substances 0.000 claims abstract description 10
- 239000002719 pyrimidine nucleotide Substances 0.000 claims abstract description 9
- 150000003230 pyrimidines Chemical class 0.000 claims abstract description 9
- 229910052742 iron Inorganic materials 0.000 claims abstract description 8
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 7
- 239000011572 manganese Substances 0.000 claims abstract description 7
- 125000004122 cyclic group Chemical group 0.000 claims abstract 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 44
- DJJCXFVJDGTHFX-ZAKLUEHWSA-N uridine-5'-monophosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-ZAKLUEHWSA-N 0.000 claims description 27
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 claims description 24
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 claims description 24
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 22
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 22
- 229940045145 uridine Drugs 0.000 claims description 22
- YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 10
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 claims description 9
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 claims description 9
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 claims description 9
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 claims description 9
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 claims description 7
- 159000000003 magnesium salts Chemical group 0.000 claims description 7
- QTPILKSJIOLICA-UHFFFAOYSA-N bis[hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(O)=O QTPILKSJIOLICA-UHFFFAOYSA-N 0.000 claims description 4
- 150000001718 carbodiimides Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 37
- 238000003786 synthesis reaction Methods 0.000 abstract description 37
- 239000002994 raw material Substances 0.000 abstract description 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 35
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 22
- CZBNYTXCJLCFMG-UHFFFAOYSA-N n,n-dibutylbutan-1-amine;n,n-dimethylformamide Chemical compound CN(C)C=O.CCCCN(CCCC)CCCC CZBNYTXCJLCFMG-UHFFFAOYSA-N 0.000 description 16
- OWTGMPPCCUSXIP-FNXFGIETSA-J tetrasodium;[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O OWTGMPPCCUSXIP-FNXFGIETSA-J 0.000 description 16
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 229940091250 magnesium supplement Drugs 0.000 description 8
- PASYJVRFGUDDEW-WMUGRWSXSA-J tetrasodium;[[(2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)[C@@H](O)C1 PASYJVRFGUDDEW-WMUGRWSXSA-J 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 7
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 7
- -1 sulfonic acid halides Chemical class 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- XCCTYIAWTASOJW-UHFFFAOYSA-N UDP-Glc Natural products OC1C(O)C(COP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229960002337 magnesium chloride Drugs 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 150000003833 nucleoside derivatives Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 4
- 229940048102 triphosphoric acid Drugs 0.000 description 4
- 150000003751 zinc Chemical class 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000012799 strong cation exchange Methods 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- JNZJYMXXPMPJCY-UHFFFAOYSA-L C(=O)N(C)C.O.O.O.O.O.O.[Cl-].[Mg+2].[Cl-] Chemical compound C(=O)N(C)C.O.O.O.O.O.O.[Cl-].[Mg+2].[Cl-] JNZJYMXXPMPJCY-UHFFFAOYSA-L 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100028045 P2Y purinoceptor 2 Human genes 0.000 description 1
- 101710096700 P2Y purinoceptor 2 Proteins 0.000 description 1
- 102100028070 P2Y purinoceptor 4 Human genes 0.000 description 1
- 108050009478 P2Y purinoceptor 4 Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- DGMKZWZRSFUOBY-UHFFFAOYSA-N iron;trifluoromethanesulfonic acid Chemical compound [Fe].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F DGMKZWZRSFUOBY-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 description 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 description 1
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 description 1
- 229910001641 magnesium iodide Inorganic materials 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000003015 phosphoric acid halides Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- MMJGIWFJVDOPJF-LLWADOMFSA-K trisodium;[[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OP(O)([O-])=O)O[C@H]1N1C(=O)NC(=O)C=C1 MMJGIWFJVDOPJF-LLWADOMFSA-K 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- FKDLMEIMIILPHT-UHFFFAOYSA-L zinc N,N-dimethylformamide dichloride Chemical compound [Cl-].[Cl-].[Zn++].CN(C)C=O FKDLMEIMIILPHT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
〔4〕金属塩がマグネシウム塩である、上記〔1〕記載の製造法。
〔5〕15〜30℃の温度条件で反応させる、上記〔1〕記載の製造法。
ウリジン5’−トリリン酸(UTP)3ナトリウム5.00g(9.10mmol)を脱イオン水に溶解して50mLとし、強カチオン交換カラム(pK216−プロトン型、27cc)に通過させ、洗浄液とあわせてトリブチルアミン8.7mL(37mmol)で中和した。この溶液を減圧下濃縮後、残渣をジオキサン20mLで4回共沸した。残渣をジメチルホルムアミド50mLに溶解し、0.15M UTPトリブチルアミン塩ジメチルホルムアミド溶液とした。この溶液にジイソプロピルカルボジイミド1535μL(10.0mmol)を加え、室温で3時間撹拌して0.15M cUTPトリブチルアミン塩ジメチルホルムアミド溶液とした。
2.05M UMP水溶液4.4mL(9.0mmol)にトリブチルアミン4.4mL(19mmol)を加え濃縮した。残渣をジオキサン20mLで6回共沸した後、ジメチルホルムアミド50mLに溶解し、0.18M UMPトリブチルアミン塩ジメチルホルムアミド溶液とした。
上記(1)の0.15M cUTPトリブチルアミン塩ジメチルホルムアミド溶液500μL(75.0μmol)に、上記(2)の0.18M UMPトリブチルアミン塩ジメチルホルムアミド溶液500μL(90.0μmol)、及び表1に示される各種金属塩の0.45Mジメチルホルムアミド溶液200μL(90.0μmol)を加え、室温(25℃)で1時間反応させた。反応液をHPLC(262nm)により分析し、目的とするUp4Uの合成収率を求めた。その結果を表1に示す。
UTP3ナトリウム塩1.00g(1.82mmol)を脱イオン水13mLに溶解し、強カチオン交換カラム(pK216−プロトン型、10cc)に通過させ、洗浄液とあわせてトリブチルアミン1.75mL(7.35mmol)で中和した。この溶液を減圧下濃縮後、残渣をジオキサン10mLで4回共沸した。残渣をジメチルホルムアミド10mLに溶解し、0.133M UTPトリブチルアミン塩ジメチルホルムアミド溶液とした。
2.05M UMP水溶液1.06mL(2.18mmol)にトリブチルアミン1.06mL(4.46mmol)を加え濃縮した。残渣をジオキサン10mLで4回共沸した後、ジメチルホルムアミド10mLに溶解し、0.184M UMPトリブチルアミン塩ジメチルホルムアミド溶液とした。
上記(1)のUTPトリブチルアミン塩ジメチルホルムアミド溶液にジイソプロピルカルボジイミド364μL(2.37mmol)を加え、室温で3時間撹拌した。ここに上記(2)の0.18M UMPトリブチルアミン塩ジメチルホルムアミド溶液及び無水塩化マグネシウム207.5mg(2.179mmol)をジメチルホルムアミド4.9mLに溶解した溶液を加え、室温で255分間撹拌した。得られた液をHPLC(262nm)で分析した結果、UTPから合成収率84.2%で目的とするUp4Uが生成していることが明らかとなった。
上記(3)の反応溶液に脱イオン水6.5mLを加え、減圧下濃縮した。残渣に脱イオン水25mLを加えて生じた沈殿を濾去後、濾液、洗液をあわせて強カチオン交換カラム(pK216−プロトン型、20cc)に通過させた。通過液、洗液をあわせてトリエチルアミンでpH7.5とした。この溶液をアニオン交換カラム(IRA67−塩化物イオン型、40cc)に吸着させ、0.15N塩酸、脱イオン水で順次洗浄後、目的物を0.3−0.4M炭酸水素アンモニウム水溶液で溶出した。目的物を含むフラクションを減圧下濃縮後、残渣を脱イオン水で共沸、凍結乾燥した。得られた残渣を脱イオン水に溶解後、強カチオン交換カラム(pK216−ナトリウム型、40cc)に通過させ、溶出液、洗浄液を合わせて減圧下濃縮した。残渣を脱イオン水に溶解後、エタノールを加え冷却した。析出した結晶を濾取し、Up4U・ナトリウム塩を得た(1.08g、1.23mmol、67.7%)
0.15M cUTPトリブチルアミン塩ジメチルホルムアミド溶液500μL(75.0μmol)、0.154Mウリジン5’−ジリン酸(UDP)トリブチルアミン塩ジメチルホルムアミド溶液584μL(90.0μmol)、0.45M無水塩化マグネシウムジメチルホルムアミド溶液200μL(90.0μmol)を加え、室温で72時間撹拌した。得られた液をHPLC(262nm)で分析した結果、UTPから合成収率50.5%で目的とするUp5Uが生成していることが明らかとなった。
Claims (9)
- 縮合剤を用いてピリミジンヌクレオシド5’−トリリン酸をピリミジンヌクレオシド5’−環状トリリン酸へ変換し、続けてマグネシウム、マンガン及び鉄から選択された金属塩の存在下、得られたピリミジンヌクレオシド5’−環状トリリン酸とピリミジンヌクレオチドとを反応させることを特徴とするジ(ピリミジンヌクレオシド5’−)ポリホスフェートの製造法。
- 縮合剤がカルボジイミド類である、請求項1記載の製造法。
- 金属塩がマグネシウム塩である、請求項1記載の製造法。
- 15〜30℃の温度条件で反応させる、請求項1記載の製造法。
- ウリジン5’−トリリン酸とウリジン5’−モノリン酸を用い、P1,P4−ジ(ウリジン5’−)テトラホスフェートを製造する、請求項1記載の製造法。
- ウリジン5’−トリリン酸とウリジン5’−ジリン酸を用い、P1,P5−ジ(ウリジン5’−)ペンタホスフェートを製造する、請求項1記載の製造法。
- ウリジン5’−トリリン酸と2’−デオキシシチジン5’−モノリン酸を用い、P1−(2’−デオキシシチジン5’−)P4−(ウリジン5’−)テトラホスフェートを製造する、請求項1記載の製造法。
- 2’−デオキシシチジン5’−トリリン酸とウリジン5’−モノリン酸とを用い、P1−(2’−デオキシシチジン5’−)P4−(ウリジン5’−)テトラホスフェートを製造する、請求項1記載の製造法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008526680A JP5193040B2 (ja) | 2006-07-26 | 2007-07-25 | ジ(ピリミジンヌクレオシド5’−)ポリホスフェートの製造法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006203124 | 2006-07-26 | ||
JP2006203124 | 2006-07-26 | ||
JP2008526680A JP5193040B2 (ja) | 2006-07-26 | 2007-07-25 | ジ(ピリミジンヌクレオシド5’−)ポリホスフェートの製造法 |
PCT/JP2007/000793 WO2008012949A1 (fr) | 2006-07-26 | 2007-07-25 | Procédé servant à produire un di(nucléoside pyrimidique-5'-)polyphosphate |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2008012949A1 true JPWO2008012949A1 (ja) | 2009-12-17 |
JP5193040B2 JP5193040B2 (ja) | 2013-05-08 |
Family
ID=38981265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008526680A Active JP5193040B2 (ja) | 2006-07-26 | 2007-07-25 | ジ(ピリミジンヌクレオシド5’−)ポリホスフェートの製造法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8193338B2 (ja) |
EP (1) | EP2045257B1 (ja) |
JP (1) | JP5193040B2 (ja) |
KR (1) | KR101406102B1 (ja) |
CN (1) | CN101495497B (ja) |
CA (1) | CA2659595C (ja) |
WO (1) | WO2008012949A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010150791A1 (ja) * | 2009-06-23 | 2010-12-29 | ヤマサ醤油株式会社 | アデノシンテトラホスフェート化合物の製造法 |
US10179799B2 (en) | 2012-12-28 | 2019-01-15 | Yamasa Corporation | Method for producing P1,P4-di(uridine 5′-) tetraphosphate |
CN103923143B (zh) * | 2014-04-10 | 2017-01-11 | 江西科技师范大学 | 一种合成双核苷四磷酸以及p2,p3-(双卤代)亚甲基双核苷四磷酸的方法 |
CN104262438A (zh) * | 2014-08-18 | 2015-01-07 | 江西科技师范大学 | 一种合成对称双核苷三磷酸、四磷酸和五磷酸钠盐的方法 |
JPWO2017002827A1 (ja) | 2015-06-29 | 2018-04-26 | ヤマサ醤油株式会社 | P1,p4−ビス(5’−ウリジル)テトラホスフェート結晶の保管方法 |
US10815263B2 (en) | 2016-10-25 | 2020-10-27 | Yamasa Corporation | Method for purifying P1,P4-di(uridine 5′-)tetraphosphate |
WO2018080227A2 (ko) * | 2016-10-27 | 2018-05-03 | 에스케이씨 주식회사 | 보호필름, 편광판 및 이를 포함하는 표시장치 |
CN107056859A (zh) * | 2017-04-28 | 2017-08-18 | 广东众生药业股份有限公司 | 一种高纯度p1,p4‑二(尿苷‑5’‑四磷酸)盐的制备方法 |
CN108164577A (zh) * | 2017-04-28 | 2018-06-15 | 广东众生药业股份有限公司 | 一种p1,p4-二(尿苷-5’-四磷酸)钠盐的工业化制备方法 |
KR102504764B1 (ko) * | 2017-06-21 | 2023-03-02 | 주식회사 종근당 | 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법 |
CN109305991B (zh) * | 2017-07-27 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 一种p1,p4-二(尿苷5’-)四磷酸钠的制备方法 |
KR101985791B1 (ko) * | 2017-07-27 | 2019-06-05 | (주)리독스바이오 | 디(뉴클레오시드 5'-)폴리포스페이트의 제조 방법 |
KR101934448B1 (ko) * | 2017-10-17 | 2019-01-02 | 에스케이씨 주식회사 | 편광판용 보호필름 및 이를 포함하는 액정표시장치 |
KR20180091689A (ko) | 2017-11-06 | 2018-08-16 | 주식회사 종근당 | 무정형 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법 |
CN110218233B (zh) * | 2018-03-01 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种p1,p4-二(尿苷5`-)四磷酸盐的制备方法 |
CN110655545B (zh) * | 2018-06-28 | 2022-09-09 | 上海致根医药科技有限公司 | P1,p4-二(尿苷5’-)四磷酸酯的制备方法 |
KR20200106738A (ko) | 2019-03-05 | 2020-09-15 | 주식회사 파마코스텍 | P1,p4-디(우리딘 5'-)테트라포스페이트, 이의 염 또는 이의 수화물의 신규한 제조방법 |
CN110590887B (zh) * | 2019-09-04 | 2020-12-15 | 江苏金殳医药科技有限公司 | 一种磷酸酯的制备方法 |
CN110804081A (zh) * | 2019-12-09 | 2020-02-18 | 美亚药业海安有限公司 | 一种地夸磷索杂质的合成方法 |
CN111116694B (zh) * | 2020-01-02 | 2021-10-08 | 上海方予健康医药科技有限公司 | P1,p4二(尿苷5’-)四磷酸盐的制备方法 |
CN111662350B (zh) * | 2020-07-07 | 2022-06-07 | 南京宸翔医药研究有限责任公司 | 一种绿色化智能化高纯度地夸磷索四钠的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837861A (en) | 1997-02-10 | 1998-11-17 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
DK0981534T3 (da) * | 1997-02-06 | 2006-09-04 | Inspire Pharmaceuticals Inc | Dinukleotider og deres anvendelser |
BRPI9810436B1 (pt) | 1997-07-25 | 2015-12-29 | Inspire Pharmaceuticals Inc | processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo |
-
2007
- 2007-07-25 US US12/375,152 patent/US8193338B2/en active Active
- 2007-07-25 JP JP2008526680A patent/JP5193040B2/ja active Active
- 2007-07-25 EP EP07790287.2A patent/EP2045257B1/en active Active
- 2007-07-25 CA CA2659595A patent/CA2659595C/en active Active
- 2007-07-25 KR KR1020097000727A patent/KR101406102B1/ko active IP Right Grant
- 2007-07-25 CN CN2007800286469A patent/CN101495497B/zh active Active
- 2007-07-25 WO PCT/JP2007/000793 patent/WO2008012949A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN101495497A (zh) | 2009-07-29 |
CA2659595C (en) | 2016-01-19 |
EP2045257B1 (en) | 2016-08-17 |
US20100016567A1 (en) | 2010-01-21 |
US8193338B2 (en) | 2012-06-05 |
CA2659595A1 (en) | 2008-01-31 |
KR101406102B1 (ko) | 2014-06-11 |
KR20090032077A (ko) | 2009-03-31 |
JP5193040B2 (ja) | 2013-05-08 |
WO2008012949A1 (fr) | 2008-01-31 |
CN101495497B (zh) | 2012-03-14 |
EP2045257A4 (en) | 2012-02-15 |
EP2045257A1 (en) | 2009-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5193040B2 (ja) | ジ(ピリミジンヌクレオシド5’−)ポリホスフェートの製造法 | |
JP7373598B2 (ja) | ジヌクレオシドポリリン酸化合物の製造方法 | |
DK2940030T3 (en) | METHOD OF PREPARING P1, P4-DI (URIDIN 5 '-) TETRAPHOSPHATE | |
JP3247685B2 (ja) | ジウリジンテトラホスフェート又はその塩の結晶及びその製造法、並びに該化合物の製造法 | |
WO2016110761A1 (en) | PROCESS FOR PRODUCING 1-β-D-ARABINOFURANOSYLCYTOSINE AND 2,2'-O-CYCLOCYTIDINE | |
JP5599078B2 (ja) | アデノシンテトラホスフェート化合物の製造法 | |
KR20200106738A (ko) | P1,p4-디(우리딘 5'-)테트라포스페이트, 이의 염 또는 이의 수화물의 신규한 제조방법 | |
JP2023511656A (ja) | ウリジン5’-二リン酸(udp)、その塩またはその水和物の製造方法 | |
JPS5930720B2 (ja) | 5−ブロモウラシルヌクレオシドの製造法 | |
JP2003246793A (ja) | ジヌクレオチドの製造法 | |
JPH027597B2 (ja) | ||
JPS6075493A (ja) | シチジン誘導体の製造法 | |
JP2002053591A (ja) | 2’−o−アルキルグアノシンの製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100114 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120906 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130201 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5193040 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160208 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |